Revenue Breakdown
Composition ()
No data
Revenue Streams
Profitability & Margins
Evaluating the bottom line, Addex Therapeutics Ltd maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -1403.58%, while the net margin is -3179.90%. These profitability ratios, combined with a Return on Equity (ROE) of -71.06%, provide a clear picture of how effectively ADXN converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, ADXN competes directly with industry leaders such as MBIO and GTBP. With a market capitalization of $9.73M, it holds a significant position in the sector. When comparing efficiency, ADXN's gross margin of 100.00% stands against MBIO's N/A and GTBP's N/A. Such benchmarking helps identify whether Addex Therapeutics Ltd is trading at a premium or discount relative to its financial performance.
